Cigna Group FY26 Results: Adj EPS guidance $30.45 beats estimate

0 min read | Published on 30 Sept 2026, 05:25 PM |Updated on 30 Sept 2026, 05:25 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Cigna Group guides FY26 adjusted EPS to at least $30.45, beating the $30.41 estimate
FY26 revenue expected to be ~$280.000B, below the $285.608B analyst forecast
Adjusted EPS exceeds estimates by $0.04 per share
Revenue projection trails consensus by approximately $5.608B

*this image is generated using AI for illustrative purposes only.

Cigna Group (NYSE: CI) projected FY26 adjusted earnings per share of at least $30.45, exceeding the analyst estimate of $30.41. This guidance signals a slight beat on profitability metrics for the upcoming fiscal year.

Revenue and Profit Guidance

The company also provided revenue expectations for FY26, forecasting approximately $280.000B. This figure sits below the consensus estimate of $285.608B, indicating a divergence between top-line projections and earnings expectations.

Metric	Cigna Guidance	Analyst Estimate	Difference
Adjusted EPS	At least $30.45	$30.41	+$0.04
Revenue	~$280.000B	$285.608B	-$5.608B

What the Numbers Show

The guidance presents a mixed signal: while adjusted EPS is set to marginally outperform estimates, the revenue projection falls short of the consensus by over $5.6 billion. This suggests that Cigna anticipates maintaining or improving margins despite a lower-than-expected top-line performance.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the $5.6 billion revenue shortfall impact Cigna's strategic investments in its Evernorth health services segment?

What specific margin expansion initiatives is Cigna relying on to offset lower top-line growth in FY26?

How might competitors like UnitedHealth Group adjust their own FY26 guidance in response to Cigna's conservative revenue outlook?

Cigna Group delivers 10.49% annualized return over 20 years

1 min read | Published on 28 Aug 2026, 03:52 AM |Updated on 28 Aug 2026, 03:52 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Cigna Group delivered an annualized return of 10.49% over the last 20 years
The stock outperformed the broader market by 1.25% annually during this period
A $1,000 investment made two decades ago is now valued at $7,359.40
The company currently trades at a market capitalization of $73.46 billion
Current share price stands at $278.00 as of the report date

*this image is generated using AI for illustrative purposes only.

Cigna Group (NYSE: CI) has generated an average annual return of 10.49% over the past 20 years, outperforming the broader market by 1.25% on an annualized basis.

The healthcare services company currently holds a market capitalization of $73.46 billion. This valuation reflects the cumulative impact of long-term price appreciation and dividend reinvestment for shareholders who have held the stock through various market cycles.

Investment Performance Snapshot

The power of compounding is evident in the long-term trajectory of CI shares. An investor who purchased $1,000 worth of Cigna Group stock 20 years ago would see that position grow to $7,359.40 today. This calculation assumes a share price of $278.00 at the time of writing.

Metric	Value
Annualized Return	10.49%
Market Outperformance	1.25%
Current Market Cap	$73.46 billion
Current Share Price	$278.00

What the Numbers Show

The data highlights a significant divergence between nominal capital preservation and real wealth creation through equity ownership in large-cap healthcare. While the absolute return of roughly 7.3x on initial capital appears modest compared to high-growth tech sectors of the same era, the consistent outperformance against the broader market benchmark suggests a defensive quality to the stock’s returns. The current market capitalization of $73.46 billion indicates that this historical performance has translated into substantial enterprise scale, supporting the company's ability to sustain operations and shareholder distributions.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might evolving healthcare regulations and Medicare Advantage policy changes impact Cigna's ability to sustain its historical outperformance?

Given the current $73.46 billion market cap, what strategic M&A opportunities or divestitures could drive the next phase of growth for Cigna?

Can Cigna maintain its defensive return profile against broader market volatility amidst rising interest rates and shifting investor sentiment toward value stocks?